Is Atea undervalued or overvalued?
As of 2025-03-20, the Intrinsic Value of Atea Pharmaceuticals Inc (AVIR) is -49.84 USD. This Atea valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.17 USD, the upside of Atea Pharmaceuticals Inc is -1,672.30%. This means that Atea is overvalued by 1,672.30%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -49.84 - -49.84 | -49.84 | -1,672.30% |
| P/E | (33.65) - (37.20) | (36.68) | -1257.2% |
| DDM - Stable | (12.64) - (31.44) | (22.04) | -795.4% |
| DDM - Multi | (8.31) - (16.63) | (11.14) | -451.5% |
| Market Cap (mil) | 267.74 |
| Beta | 1.08 |
| Outstanding shares (mil) | 84.46 |
| Enterprise Value (mil) | 203.04 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.37% |
| Cost of Debt | 5.00% |
| WACC | 8.66% |